Welcome to Arakena Pharmaceuticals!
We are a Swiss biopharmaceutical start-up company focusing on novel cardiovascular therapies.
We want to discover and develop GRK5 inhibitors as a first-in-class treatment for cardiomyopathies.
Our Asset
- We received an exclusive option-to-license intellectual property from a major US-based university and pioneer in the field of GPCR kinases.
- Our asset consists of three structural classes of highly potent and drug-like compounds with various GRK selectivity profiles, including selective GRK5 and GRK2 inhibitors.
- The intellectual property is well protected by patents that will remain valid beyond 2040.
Why Cardiomyopathies?
Cardiovascular diseases are the leading cause of death globally, taking an estimated 18 million lives every year.
The WHO estimates that at least one million deaths are due to a cardiomyopathy.
That is Why We Founded Arakena
Arakena Pharmaceuticals was founded in 2024 by three scientists with a shared vision and decades of experience in pharma. Having already contributed to the development and approval of several successful medications, we teamed up to turn our passion for drug discovery into a company. Now, we’re bringing our know-how to the next chapter—science with purpose, built from experience.
Our Mission
Acute/chronic organ injuries often lead to disease progression and organ failure. We aim to protect organs and reverse the path to organ failure.
Our Vision
Create a world-leading biopharmaceutical company. Discover and develop novel, highly efficacious and safe compounds with life-saving potential in cardiomyopathy.
How We Do It
In-license mid-staged discovery compounds: Validated concepts and potential for first-in-class and unmet medical need.
Use AI-assisted decision making tools: Rapidly identify efficacious compounds with excellent safety profile.
Value creation: Establish PCC-ready compound, demonstrate efficacy and MoA in models of target disease to initiate preclinical / clinical development.
1st Project identified: Exclusive option to license IP agreement with major US University.
What Our Experts Say
“As a startup our goal is to launch innovation and make it market-ready, helping patients when they need it the most.”
“By combining our passion for science with our more than 60 years of experience in the pharmaceutical industry, we will turn research into innovative medicines.”
“At Arakena, we have built a network of highly experienced experts and consultants who will help us bring our inventions to patients.”